Who are AT-527 single dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ribavirin "loading" dose given, D: Peg-interferon alpha-2a & Ribavirin, pegylated interferon alpha 2a, ribavirin, standard treatment COVID-19 + Triazavirin, Infergen and ribavirin, E: Peg-interferon alpha-2a & Ribavirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/at-527-single-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AT-527 single dose — Competitive Intelligence Brief

AT-527 single dose (AT-527 single dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: nucleoside analog. Area: Infectious Disease.

phase 1 nucleoside analog viral RNA-dependent RNA polymerase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

AT-527 single dose (AT-527 single dose) — Atea Pharmaceuticals, Inc.. AT-527 is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, thereby blocking viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AT-527 single dose TARGET	AT-527 single dose	Atea Pharmaceuticals, Inc.	phase 1	nucleoside analog	viral RNA-dependent RNA polymerase
Ribavirin "loading" dose given	Ribavirin "loading" dose given	Göteborg University	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; IMPDH (inosine monophosphate dehydrogenase)
D: Peg-interferon alpha-2a & Ribavirin	D: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
pegylated interferon alpha 2a, ribavirin	pegylated interferon alpha 2a, ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
standard treatment COVID-19 + Triazavirin	standard treatment COVID-19 + Triazavirin	Ain Shams University	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase (RdRp)
Infergen and ribavirin	Infergen and ribavirin	Kadmon Corporation, LLC	marketed	Interferon alpha and nucleoside analog combination	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
E: Peg-interferon alpha-2a & Ribavirin	E: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; viral RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (nucleoside analog class)

Atea Pharmaceuticals, Inc. · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Medivir · 1 drug in this class
Tarapeutics Science Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AT-527 single dose — Competitive Intelligence Brief. https://druglandscape.com/ci/at-527-single-dose. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab